High expression of the POU factor Brn3a in aggressive neuroendocrine tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 1, 1997, Pages 89-94

  Leblond Francillard, Marie ^a   Picon, Agnès ^a   Bertagna, Xavier ^a   De Keyzer, Yves ^a  

^a INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GONADOTROPIN; GROWTH HORMONE; PROLACTIN;

ANIMAL CELL; ARTICLE; BRONCHUS CARCINOID; CARCINOGENESIS; CORTICOTROPIN RELEASE; GENE EXPRESSION REGULATION; GONADOTROPIN RELEASE; GROWTH HORMONE RELEASE; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROLACTIN RELEASE; PROMOTER REGION; TRANSCRIPTION REGULATION;

ADENOMA; ADRENOCORTICOTROPIC HORMONE; ANIMALS; BRONCHIAL NEOPLASMS; DNA; DNA-BINDING PROTEINS; GENE EXPRESSION; HUMAN GROWTH HORMONE; HUMANS; MICE; MICE, NUDE; NEUROENDOCRINE TUMORS; PITUITARY NEOPLASMS; PRO-OPIOMELANOCORTIN; PROLACTINOMA; RNA, MESSENGER; TRANSCRIPTION FACTOR BRN-3; TRANSCRIPTION FACTOR BRN-3A; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

ANIMALIA; BRONCHUS;

EID: 0031036542     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.1.89     Document Type: Article

References (22)

1. Jeanotte L, Trifiro MA, Plante RK, Chamberland M, Drouin J. 1987 Tissue-specific activity of the pro-opiomelanocortin gene promoter. Mol Cell Biol. 7:4058-4064.
2. Tremblay Y, Tretjakoff I, Ptetson A, Antakly T, Xian Zhang C, Diouin J. 1988 Pituitary-specific expression and glucocorticoid regulation of a pro-opiomelanocortin fusion gene in transgenic mice. Proc Natl Acad Sci USA. 85:8890-8894.
3. Therrien M, Drouin J. 1991 Pituitary pro-opiomelanocortin gene expression requires synergistic interactions of several regulatory elements. Mol Cell Biol. 11:3492-3503.
4. Therrien M, Drouin J. 1993 Cell-specific helix-loop-helix factor required for pituitary expression of the proopiomelanocortin gene. Mol Cell Biol 13:2342-2353.
5. Gerrero MR, McEvilly RJ, Turner E, et al. 1993 Brn-3.0: a POU-domain protein expressed in the sensory, immune, and endocrine systems that functions on elements distinct from known octamer motifs. Proc Natl Acad Sci USA. 90:10841-10845.
6. Li P, He X, Gerrero MR, Mok M, Aggarwal A, Rosenfeld MG. 1993 Spacing and orientation of bipartite DNA-binding motifs as potential functional determinants for POU domain factors. Genes Dev 2483-2496.
7. Theil T, McLean-Hunter S, Zörnig M, Möröy T. 1993 Mouse BRN-3 family of POU transcription factors: a new aminoterminal domain is crucial for the oncogenic activity of BRN-3A. Nucleic Acids Res. 21:5921-5929.
8. Collum RG, Fisher PE, Datta M, et al. 1992 A novel POU homeodomain gene specifically expressed in cells of the developint mammalian nervous system. Nucleic Acids Res. 20:4919-4925.
9. Bhargava AK, Li Z, Weissman SM. 1993 Differential expression of four members of the POU family of proteins in activated and phorbol 12-myristate 13-acetate-treated Jurkat T cells. Proc Natl Acad Sci USA. 90:10260-10264.
10. Warren WH, Gould VE, Faber LP, Kittle CF, Memoli VA. 1985 Neuroendocrine neoplasms of the bronchopulmonary tract. A classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. J Thorac Cardiovasc Surg. 89:819-825.
11. Picon A, Leblond-Francillard M, Raffin-Sanson M-L, Lenne F, Bertagna X, de Keyzer Y. 1995 Functional analysis of the human proopiomelanocortin promoter in the small cell lung carcinoma cell line DMS 79. J Mol Endocrinol. 15:187-194.
12. Poupon MF, Arvelo F, Goguel AF, et al. 1993 Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst. 85:2023-2029.
13. de Keyzer Y, Bertagna X, Lenne F, Girard F, Luton J-P, Kahn A. 1985 Altered proopiomelanocortin gene expression in ACTH producing non-pituitary tumors. J Clin Invest. 76:1892-1898.
14. Bertagna X, Stone WJ, Nicholson WE, Mount CD, Orth DN. 1981 Simultaneous assay of immunoreactive β-lipotropin, γ-lipotropin, and β-endorphin in plasma of normal human subjects, patients with ACTH/LPH hypersecretory syndromes, and patients undergoing chronic hemodialysis. J Clin Invest. 67:124-133.
15. Chirwing JM, Przybyla AE, MacDonald RJ, Rutter WJ. 1979 Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:5294-5299.
16. Chomczynski P, Sacchi N. 1987 Single-step method of RNA isolation by acid guanidinium thyocyanate-phenol-chloroform extraction. Anal Biochem. 162:156-159.
17. Helin K, Wu CL, Fattaey AR. 1993 Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev. 7:1850-1861.
18. Kadonaga JT, Tjian R. 1986 Affinity purification of sequence-specific DNA binding proteins. Proc Natl Acad Sci USA. 83:5889-5893.
19. Vieau D, Rojas-Miranda A, Verley JM, Lenne F, Bertagna X. 1991 The secretory granule peptides 7B2 and CCB are sensitive biochemical markers of neuro-endocrine bronchial tumors in man. Clin Endocrinol (Oxf). 35:319-325.
20. Creemers J, Roebroek A, Van de Ven W. 1992 Expression in human lung tumor cells of the proprotein processing enzyme PC1/PC3: cloning and primary sequence of a 5Kb cDNA. FEBS Lett. 300:82-88.
21. Vieau D, Seidah NG, Chrétien M, Bertagna X. 1994 Expression of the prohormone convertase PC2 correlates with the presence of CLIP in human ACTH secreting tumors. J Clin Endocrinol Metab. 79:1503-1509.
22. Scopsi L, Gullo M, Rilke F, Martin S, Steiner DF. 1995 Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differenciation. J Clin Endocrinol Metab. 80:294-301.